End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,917 MXN | -3.26% |
|
0.00% | +0.20% |
Jun. 17 | Charles River Laboratories, Captain T Cell Enter Manufacturing Deal | MT |
Jun. 13 | Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2024 P/E ratio at 26.38 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.20% | 10.81B | - | ||
+34.01% | 51.07B | B- | ||
-8.02% | 38.78B | B | ||
+35.28% | 38.86B | A | ||
-11.12% | 26.69B | C | ||
+12.56% | 26.35B | B- | ||
-19.62% | 19.46B | B | ||
+39.18% | 13.58B | B+ | ||
+31.47% | 12.46B | C+ | ||
-3.40% | 11.75B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- CRL * Stock
- Ratings Charles River Laboratories International, Inc.